Do analysts rate BPCP or EMG?

Man Group has a consensus target price of GBX 304.75, indicating a potential downside of 7.65%. Given Man Group's stronger consensus rating and higher possible upside, analysts plainly believe Man Group is more favorable than BioPharma Credit. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioPharma Credit 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Man Group 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation & earnings, BPCP or EMG?

Man Group has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than Man Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioPharma Credit £95.48M 10.61 £130.67M £6.77 10.90 Man Group £1.69B 2.16 £382.68M £28.10 11.74

Does the media favor BPCP or EMG?

In the previous week, BioPharma Credit and BioPharma Credit both had 1 articles in the media. BioPharma Credit's average media sentiment score of 1.79 beat Man Group's score of 0.19 indicating that BioPharma Credit is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioPharma Credit 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Man Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BPCP or 3IN?

3i Infrastructure has a consensus price target of GBX 450, suggesting a potential upside of 14.21%. Given 3i Infrastructure's stronger consensus rating and higher probable upside, analysts clearly believe 3i Infrastructure is more favorable than BioPharma Credit. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioPharma Credit 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 3i Infrastructure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to BPCP or 3IN?

In the previous week, 3i Infrastructure had 4 more articles in the media than BioPharma Credit. MarketBeat recorded 5 mentions for 3i Infrastructure and 1 mentions for BioPharma Credit. BioPharma Credit's average media sentiment score of 1.79 beat 3i Infrastructure's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioPharma Credit 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive 3i Infrastructure 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioPharma Credit (BPCP) Competitors

GBX 73.76 -0.24 (-0.32%)

As of 11:30 AM Eastern

Compare

BPCP vs. EMG, 3IN, ATST, PHLL, and JGGI

Should you buy BioPharma Credit stock or one of its competitors? BioPharma Credit's main competitors and comparable companies include Man Group (EMG), 3i Infrastructure (3IN), Alliance Trust (ATST), Petershill Partners (PHLL), and JPMorgan Global Growth & Income (JGGI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "capital markets" industry.

How does BioPharma Credit compare to Man Group?

BioPharma Credit (LON:BPCP) and Man Group (LON:EMG) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.5%. Man Group pays an annual dividend of GBX 17.02 per share and has a dividend yield of 5.2%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Man Group pays out 60.6% of its earnings in the form of a dividend.

23.7% of BioPharma Credit shares are held by institutional investors. Comparatively, 47.7% of Man Group shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Comparatively, 7.7% of Man Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioPharma Credit has a net margin of 92.32% compared to Man Group's net margin of 18.60%. Man Group's return on equity of 20.41% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	92.32%	9.57%	5.33%
Man Group	18.60%	20.41%	4.61%

Man Group has a consensus target price of GBX 304.75, indicating a potential downside of 7.65%. Given Man Group's stronger consensus rating and higher possible upside, analysts plainly believe Man Group is more favorable than BioPharma Credit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioPharma Credit	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Man Group	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, BioPharma Credit and BioPharma Credit both had 1 articles in the media. BioPharma Credit's average media sentiment score of 1.79 beat Man Group's score of 0.19 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioPharma Credit	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Man Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioPharma Credit has a beta of 0.176, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Man Group has a beta of 0.631, indicating that its stock price is 37% less volatile than the broader market.

Man Group has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than Man Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£95.48M	10.61	£130.67M	£6.77	10.90
Man Group	£1.69B	2.16	£382.68M	£28.10	11.74

Summary

Man Group beats BioPharma Credit on 12 of the 17 factors compared between the two stocks.

How does BioPharma Credit compare to 3i Infrastructure?

BioPharma Credit (LON:BPCP) and 3i Infrastructure (LON:3IN) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

3i Infrastructure has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than 3i Infrastructure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£95.48M	10.61	£130.67M	£6.77	10.90
3i Infrastructure	£301M	12.07	£347M	£32.00	12.31

BioPharma Credit has a beta of 0.176, indicating that its stock price is 82% less volatile than the broader market. Comparatively, 3i Infrastructure has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

3i Infrastructure has a consensus price target of GBX 450, suggesting a potential upside of 14.21%. Given 3i Infrastructure's stronger consensus rating and higher probable upside, analysts clearly believe 3i Infrastructure is more favorable than BioPharma Credit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioPharma Credit	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
3i Infrastructure	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

3i Infrastructure has a net margin of 92.78% compared to BioPharma Credit's net margin of 92.32%. 3i Infrastructure's return on equity of 10.77% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	92.32%	9.57%	5.33%
3i Infrastructure	92.78%	10.77%	4.83%

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.5%. 3i Infrastructure pays an annual dividend of GBX 13.05 per share and has a dividend yield of 3.3%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. 3i Infrastructure pays out 40.8% of its earnings in the form of a dividend.

In the previous week, 3i Infrastructure had 4 more articles in the media than BioPharma Credit. MarketBeat recorded 5 mentions for 3i Infrastructure and 1 mentions for BioPharma Credit. BioPharma Credit's average media sentiment score of 1.79 beat 3i Infrastructure's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioPharma Credit	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
3i Infrastructure	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.7% of BioPharma Credit shares are held by institutional investors. Comparatively, 24.1% of 3i Infrastructure shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 0.1% of 3i Infrastructure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

3i Infrastructure beats BioPharma Credit on 15 of the 18 factors compared between the two stocks.

How does BioPharma Credit compare to Alliance Trust?

BioPharma Credit (LON:BPCP) and Alliance Trust (LON:ATST) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

23.7% of BioPharma Credit shares are owned by institutional investors. Comparatively, 6.9% of Alliance Trust shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 2.4% of Alliance Trust shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alliance Trust has higher revenue and earnings than BioPharma Credit. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£95.48M	10.61	£130.67M	£6.77	10.90
Alliance Trust	£652.76M	0.00	£601.66M	£2.12	N/A

BioPharma Credit has a net margin of 92.32% compared to Alliance Trust's net margin of 92.17%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	92.32%	9.57%	5.33%
Alliance Trust	92.17%	17.93%	10.95%

In the previous week, BioPharma Credit had 1 more articles in the media than Alliance Trust. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for Alliance Trust. BioPharma Credit's average media sentiment score of 1.79 beat Alliance Trust's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Overall Sentiment
BioPharma Credit	Very Positive
Alliance Trust	Neutral

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.5%. Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has a beta of 0.176, meaning that its share price is 82% less volatile than the broader market. Comparatively, Alliance Trust has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Summary

BioPharma Credit and Alliance Trust tied by winning 7 of the 14 factors compared between the two stocks.

How does BioPharma Credit compare to Petershill Partners?

BioPharma Credit (LON:BPCP) and Petershill Partners (LON:PHLL) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

In the previous week, BioPharma Credit had 1 more articles in the media than Petershill Partners. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for Petershill Partners. BioPharma Credit's average media sentiment score of 1.79 beat Petershill Partners' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Overall Sentiment
BioPharma Credit	Very Positive
Petershill Partners	Neutral

23.7% of BioPharma Credit shares are owned by institutional investors. Comparatively, 3.7% of Petershill Partners shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Comparatively, 0.1% of Petershill Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.5%. Petershill Partners pays an annual dividend of GBX 15.50 per share and has a dividend yield of 5.0%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Petershill Partners pays out 17.9% of its earnings in the form of a dividend.

Petershill Partners has higher revenue and earnings than BioPharma Credit. Petershill Partners is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£95.48M	10.61	£130.67M	£6.77	10.90
Petershill Partners	£1.15B	2.93	£420.55M	£86.43	3.59

BioPharma Credit has a beta of 0.176, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Petershill Partners has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

BioPharma Credit has a net margin of 92.32% compared to Petershill Partners' net margin of 67.97%. Petershill Partners' return on equity of 16.42% beat BioPharma Credit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	92.32%	9.57%	5.33%
Petershill Partners	67.97%	16.42%	5.95%

Summary

Petershill Partners beats BioPharma Credit on 8 of the 15 factors compared between the two stocks.

How does BioPharma Credit compare to JPMorgan Global Growth & Income?

BioPharma Credit (LON:BPCP) and JPMorgan Global Growth & Income (LON:JGGI) are both finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

23.7% of BioPharma Credit shares are owned by institutional investors. Comparatively, 7.1% of JPMorgan Global Growth & Income shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Comparatively, 0.2% of JPMorgan Global Growth & Income shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

JPMorgan Global Growth & Income has higher revenue and earnings than BioPharma Credit. BioPharma Credit is trading at a lower price-to-earnings ratio than JPMorgan Global Growth & Income, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioPharma Credit	£95.48M	10.61	£130.67M	£6.77	10.90
JPMorgan Global Growth & Income	£255.23M	13.06	£625.87M	£41.81	14.60

In the previous week, BioPharma Credit had 1 more articles in the media than JPMorgan Global Growth & Income. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for JPMorgan Global Growth & Income. BioPharma Credit's average media sentiment score of 1.79 beat JPMorgan Global Growth & Income's score of 1.17 indicating that BioPharma Credit is being referred to more favorably in the media.

Company	Overall Sentiment
BioPharma Credit	Very Positive
JPMorgan Global Growth & Income	Positive

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 9.5%. JPMorgan Global Growth & Income pays an annual dividend of GBX 22.90 per share and has a dividend yield of 3.8%. BioPharma Credit pays out 103.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. JPMorgan Global Growth & Income pays out 54.8% of its earnings in the form of a dividend.

BioPharma Credit has a net margin of 92.32% compared to JPMorgan Global Growth & Income's net margin of 91.40%. BioPharma Credit's return on equity of 9.57% beat JPMorgan Global Growth & Income's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioPharma Credit	92.32%	9.57%	5.33%
JPMorgan Global Growth & Income	91.40%	7.63%	10.62%

BioPharma Credit has a beta of 0.176, suggesting that its share price is 82% less volatile than the broader market. Comparatively, JPMorgan Global Growth & Income has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

JPMorgan Global Growth & Income beats BioPharma Credit on 9 of the 15 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPCP vs. The Competition

Export

Metric	BioPharma Credit	Capital Markets Industry	Finance Sector	LON Exchange
Market Cap	£1.01B	£5.19B	£13.52B	£2.87B
Dividend Yield	7.34%	7.52%	6.01%	6.21%
P/E Ratio	10.90	27.94	22.92	366.04
Price / Sales	10.61	1,261.02	516.94	89,364.46
Price / Cash	98.00	47.81	49.06	27.89
Price / Book	0.75	3.49	2.69	6.31
Net Income	£130.67M	£417.69M	£1.32B	£5.89B
7 Day Performance	1.21%	-0.95%	-1.08%	-0.09%
1 Month Performance	2.06%	4.76%	0.76%	10.91%
1 Year Performance	10.03%	3.81%	8.11%	17.58%

BioPharma Credit Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPCP BioPharma Credit	N/A	GBX 73.76 -0.3%	N/A	+12.0%	£1.01B	£95.48M	10.90	N/A	Positive News
EMG Man Group	1.797 of 5 stars	GBX 330 -0.8%	GBX 304.75 -7.7%	+81.8%	£3.66B	£1.69B	11.74	1,790
3IN 3i Infrastructure	1.505 of 5 stars	GBX 390 +0.5%	GBX 450 +15.4%	+9.7%	£3.60B	£301M	12.19	N/A	News Coverage Analyst Forecast
ATST Alliance Trust	N/A	N/A	N/A	N/A	£3.58B	£652.76M	600.00	3
PHLL Petershill Partners	N/A	GBX 310.50 flat	N/A	N/A	£3.36B	£1.15B	3.59	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BPCP) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioPharma Credit (BPCP) Competitors

BPCP vs. EMG, 3IN, ATST, PHLL, and JGGI

How does BioPharma Credit compare to Man Group?

Summary

How does BioPharma Credit compare to 3i Infrastructure?

Summary

How does BioPharma Credit compare to Alliance Trust?

Summary

How does BioPharma Credit compare to Petershill Partners?

Summary

How does BioPharma Credit compare to JPMorgan Global Growth & Income?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPCP vs. The Competition

BioPharma Credit Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioPharma Credit (BPCP) Competitors

BPCP vs. EMG, 3IN, ATST, PHLL, and JGGI

How does BioPharma Credit compare to Man Group?

Is BPCP or EMG a better dividend stock?

Do insiders and institutionals hold more shares of BPCP or EMG?

Is BPCP or EMG more profitable?

Do analysts rate BPCP or EMG?

Does the media favor BPCP or EMG?

Which has more volatility & risk, BPCP or EMG?

Which has preferable valuation & earnings, BPCP or EMG?

Summary

How does BioPharma Credit compare to 3i Infrastructure?

Which has higher valuation and earnings, BPCP or 3IN?

Which has more volatility and risk, BPCP or 3IN?

Do analysts prefer BPCP or 3IN?

Is BPCP or 3IN more profitable?

Is BPCP or 3IN a better dividend stock?

Does the media refer more to BPCP or 3IN?

Do institutionals & insiders hold more shares of BPCP or 3IN?

Summary

How does BioPharma Credit compare to Alliance Trust?

Do institutionals & insiders hold more shares of BPCP or ATST?

Which has preferable valuation and earnings, BPCP or ATST?

Is BPCP or ATST more profitable?

Does the media favor BPCP or ATST?

Is BPCP or ATST a better dividend stock?

Which has more risk & volatility, BPCP or ATST?

Summary

How does BioPharma Credit compare to Petershill Partners?

Does the media prefer BPCP or PHLL?

Do institutionals and insiders have more ownership in BPCP or PHLL?

Is BPCP or PHLL a better dividend stock?

Which has preferable earnings & valuation, BPCP or PHLL?

Which has more risk and volatility, BPCP or PHLL?

Is BPCP or PHLL more profitable?

Summary

How does BioPharma Credit compare to JPMorgan Global Growth & Income?

Do institutionals and insiders believe in BPCP or JGGI?

Which has stronger valuation and earnings, BPCP or JGGI?

Does the media favor BPCP or JGGI?

Is BPCP or JGGI a better dividend stock?

Is BPCP or JGGI more profitable?

Which has more risk & volatility, BPCP or JGGI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPCP vs. The Competition

BioPharma Credit Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools